Genomics of Renal Cell Cancer - Does It Provide Breakthrough?

László KOPPER1, József TÍMÁR2

11st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary
2Department of Tumor Progression, National Institute of Oncology, Budapest, Hungary


It is a strong hope that the more we characterize the pathways in an individual tumor, the better we will be able to evaluate the response to a specific therapy. Different array technologies could be powerful tools to achieve this goal, i.e. selecting patients on the basis of the genomic and/or proteomic profiles who would really benefit from the target-designed therapy. Genomic analysis of RCC accumulated ample of data which now can be exploited in clinical management of a previously almost uncontrollable disease. Beside the previously identified genetic abnormalities (VHL, MET, EGFR), CAIX seems to be a novel molecular marker of RCC. Array studies also outlined a small set of tumor markers, vimentin, galectin-3, CD74 and parvalbumin, which can define the individual histologic subtypes of RCC. We are at the beginning to take advantage of the genomic results. Some new approaches will interfere with the progression of RCC (anti-VEGF, anti-VEGFR or anti-EGFR therapies). Further novel molecular targets are available, such as HIF, HSP90 or the IFN-regulated genes, which can be used to the fine-tuning of RCC therapy. Pathology & Oncology Research, Vol 12, Nr 1, 5-11, 2006

Key words: renal cell cancer; genomics; prognostic markers; targeted therapy

Received: Jan 10, 2006; accepted: Feb 20, 2006
Correspondence: László KOPPER, 1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Üllõi út 26. Budapest H-1085, Hungary; Tel: 36-1-3170891, Fax: 36-1-3170891; E-mail:

Click here to get the full-text version in PDF!